These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3117154)

  • 61. The role of the prostanoid system in mediating the haemodynamic effects of dihydroergotamine.
    Bergqvist D; Lindblad B
    Ups J Med Sci; 1984; 89(3):227-32. PubMed ID: 6516064
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Left ventricular response to severe exertion in untethered dogs.
    Vatner SF; Franklin D; Higgins CB; Patrick T; Braunwald E
    J Clin Invest; 1972 Dec; 51(12):3052-60. PubMed ID: 4640948
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [The effect of nuclear factor erythroid-2-related factor2 on the changes of cardiac function and electrocardiogram in rats after exhausted exercise].
    Xu P; Kang T; Liu HY; Sun WW; Xie YN; Cao XB
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2016 Feb; 32(2):146-151. PubMed ID: 29931867
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Influence of nitroglycerin on hemodynamics, wall tension and oxygen consumption of the left ventricle].
    Sauer G; Jehle J; Karsch R; Kreuzer H; Neuhaus KL; Spiller P
    Z Kardiol; 1976 Sep; 65(9):753-67. PubMed ID: 823724
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of nitroglycerin, postextrasystolic potentiation, and pacing-induced ischaemia on wall motion in patients with ischaemic heart disease.
    Schwartz F; Ensslen R; Thormann J; Sesto M
    Br Heart J; 1977 Jan; 39(1):44-52. PubMed ID: 401644
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Augmented coronary blood flow response to intracoronary norepinephrine after ventricular sympathectomy.
    Brandt MA; Jones CE; Gwirtz PA
    Coron Artery Dis; 1993 Jan; 4(1):101-7. PubMed ID: 8269179
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of the serotonin-antagonist ketanserin on the function of ischaemic and normally perfused myocardium and modification by beta-1-blockade in anaesthetized normotensive dogs.
    Schad H; Heimisch W; Barankay A; Hesse S; Mendler N
    Res Exp Med (Berl); 1992; 192(5):355-65. PubMed ID: 1359617
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Exercise tolerance and compensatory sympathetic tone during beta-blockade after myocardial infarction.
    Brice G; Stone HL
    Med Sci Sports Exerc; 1986 Aug; 18(4):396-401. PubMed ID: 2875377
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of diazoxide on left ventricular performance in hypertension.
    Fiegel P; Limbourg P; Just H; Lang KF
    Eur J Clin Pharmacol; 1975 Aug; 8(6):387-92. PubMed ID: 1233239
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data.
    de Hoon JN; Poppe KA; Thijssen HH; Struijker-Boudier HA; Van Bortel LM
    Br J Clin Pharmacol; 2001 Jul; 52(1):45-51. PubMed ID: 11453889
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dihydroergotamine as a pharmacologic euglycemic clamp in the surgically traumatized rabbit.
    Mossberg KA; Taegtmeyer H
    Metabolism; 1991 Jun; 40(6):594-9. PubMed ID: 1865822
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of dihydroergotamine and etilefrine on experimentally-induced postural hypotension in dogs.
    Yamazaki R; Tsuchida K; Otomo S
    J Pharmacobiodyn; 1990 Sep; 13(9):519-24. PubMed ID: 1707454
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration.
    Aellig WH; Rosenthaler J
    Eur J Clin Pharmacol; 1986; 30(5):581-4. PubMed ID: 3758146
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacological actions of the main metabolites of dihydroergotamine.
    Müller-Schweinitzer E
    Eur J Clin Pharmacol; 1984; 26(6):699-705. PubMed ID: 6489409
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension.
    Bobik A; Jennings G; Skews H; Esler M; McLean A
    Clin Pharmacol Ther; 1981 Nov; 30(5):673-9. PubMed ID: 6794970
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dihydroergotamine decreases the blood content in the skeletal musculature but etilefrine hydrochloride in the splanchnic region in man.
    Arndt JO; Höck A; Inoue K
    Basic Res Cardiol; 1984; 79(2):244-52. PubMed ID: 6146305
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dihydroergotamine in the prevention of hypotension associated with extradural anaesthesia.
    Mattila M; Hannonen P; Puttonen E; Lappalainen S
    Br J Anaesth; 1985 Oct; 57(10):976-82. PubMed ID: 3899152
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Does dihydroergotamine reduce plasma volume?
    Bergqvist D; Lindblad B
    Acta Pharmacol Toxicol (Copenh); 1986 Feb; 58(2):144-7. PubMed ID: 3705969
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lower body negative pressure: a method to differentiate vasodilators in the intact rat.
    de Metz JE; van Zwieten PA
    Clin Sci (Lond); 1979 Dec; 57 Suppl 5():341s-342s. PubMed ID: 120235
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Relationship between the venoconstrictor activity of dihydroergotamine and its pharmacokinetics during acute and chronic oral dosing.
    de Marées H; Welzel D; de Marées A; Klotz U; Tiedjen KU; Knaup G
    Eur J Clin Pharmacol; 1986; 30(6):685-9. PubMed ID: 3533566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.